News & Media


  • 20 May 2015 | Strategia Therapeutics presents E6201 at 2015 Texas Life Science Forum

    Strategia Therapeutics presents E6201, a targeted TKI for acute myeloid leukemia, at the 2015 Texas Life Science Forum Strategic Therapeutics, inc. (ST) was founded as Boston Strategics Corporation in Massachusetts in April 2012, and in November, 2013, opened an office in Houston in the vicinity of the Texas Medical Center. The company name was changed […]

  • 05 May 2015 | PEGS Boston: The essential protein engineering summit

    TAPBOOST Technology: Novel Technology to Enhance the Production of Hard-to-Produce Therapeutic Recombinant Proteins

  • 12 January 2015 | 2015 PEP Talk

    TapBoost® Technology: Broad Spectrum of Use for Novel Chaperone-driven Platform. Abstract Dr. Akinori Hishiya discovered the specific amino acid sequence that enhances protein production and named “BSC1” sequence, the core component of the TAPBOOST® technology platform. This exciting chaperone-driven productivity enhancement exploits the BSC1 sequence to 1) enhance biotherapeutic protein and antibody yields, 2) rescue difficult-to-express […]